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A B S T R A C T
Purpose
Mindfulness-based cognitive therapy (MBCT) has been shown to alleviate psychological distress in
patients with cancer. However, patients experience barriers to participating in face-to-face MBCT.
Individual Internet-based MBCT (eMBCT) could be an alternative. The study aim was to compare
MBCT and eMBCT with treatment as usual (TAU) for psychological distress in patients with cancer.
Patients and Methods
We obtained ethical and safety approval to include 245 patients with cancer with psychological
distress ($ 11 on the Hospital Anxiety and Depression Scale) in the study. They were randomly
allocated to MBCT (n = 77), eMBCT (n = 90), or TAU (n = 78). Patients completed baseline (T0) and
postintervention (T1) assessments. The primary outcome was psychological distress on the Hospital
Anxiety and Depression Scale. Secondary outcomes were psychiatric diagnosis, fear of cancer re-
currence, rumination, health-related quality of life, mindfulness skills, and positive mental health.
Continuous outcomes were analyzed using linear mixed modeling on the intention-to-treat sample.
Because both interventions were compared with TAU, the type I error rate was set at P , .025.
Results
Compared with TAU, patients reported significantly less psychological distress after both MBCT
(Cohen’s d, .45; P , .001) and eMBCT (Cohen’s d, .71; P , .001) . In addition, post-treatment
prevalence of psychiatric diagnosis was lower with both MBCT (33% improvement; P = .030) and
eMBCT (29% improvement; P = .076) in comparison with TAU (16%), but these changes were not
statistically significant. Both interventions reduced fear of cancer recurrence and rumination, and
increased mental health–related quality of life, mindfulness skills, and positive mental health
compared with TAU (all Ps, .025). Physical health–related quality of life did not improve (P = .343).
Conclusion
Compared with TAU, MBCT and eMBCT were similarly effective in reducing psychological distress
in a sample of distressed heterogeneous patients with cancer.
J Clin Oncol 36:2413-2421. © 2018 by American Society of Clinical Oncology
INTRODUCTION
From 2025 onward, 20 million people worldwide
will be diagnosed with cancer each year.1 Ap-
proximately one third of patients with cancer
suffer from significant psychological distress,2
resulting in reduced quality of life, decreased
compliance with medical care, and prolonged
duration of hospital stay.3,4 The prevalence of
psychiatric disorders in oncologic settings is 30%
to 40%.3 Effective and accessible interventions are
needed to reduce psychological distress and
psychiatric disorders in patients with cancer.
Mindfulness-based interventions (MBIs)5,6
such as mindfulness-based cognitive therapy
(MBCT), teach participants to be more mindful
in daily life through meditation exercises, yoga,
group discussions, and didactic teaching.5 A 2012
meta-analysis of randomized controlled trials
(RCTs) of MBIs in 955 patients with cancer found
significant improvements in depressive and anxiety
symptoms.7 Since then, a number of RCTs have
confirmed this.8-13
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However, because MBIs typically require in-person atten-
dance at classes over several weeks, many patients with cancer
experience barriers to participation. These may include impair-
ments due to illness and anticancer treatments, adverse effects that
result in advice to avoid groups of people, or limited transportation
options.14 Consequently, uptake of face-to-face interventions for
patients with cancer has been lower than, for instance, telephone-
based interventions.15
In contrast, Internet-based interventions are easily accessible
and save traveling time.16 Therapist-guided Internet interventions
have been shown to be effective for psychiatric and somatic
conditions.17 Although evidence for Internet-based MBIs (eMBIs)
in cancer is scarce, one controlled study of 62 patients found that
synchronous videoconferencing sessions led to significant im-
provements in mood, stress symptoms, andmindfulness skills,18 In
addition, an uncontrolled cohort of 257 fatigued patients showed
significant improvements in fatigue and psychological distress after
individual eMBCT.19
To date, no study has simultaneously compared the effec-
tiveness of both MBCT and Internet-based MBCT (eMBCT) with
treatment as usual (TAU). The primary aim of this RCT was to
investigate whether MBCTand eMBCTwere each superior to TAU
in reducing psychological distress in a sample of distressed patients
with cancer. Moreover, we hypothesized that there would be
a reduction of psychiatric diagnoses, fear of cancer recurrence, and
rumination, and an improvement in health-related quality of life,
mindfulness skills, and positive mental health in both interventions
compared with TAU. We explored moderators of intervention
dropout and outcome in the interventions: sex, age, cancer di-
agnosis, anticancer treatment intent, psychiatric diagnosis, neu-
roticism, and therapist.
PATIENTS AND METHODS
Trial Design
A three-armed multicenter, parallel group RCT was conducted to
compare the effectiveness of MBCT and eMBCT with TAU in reducing
psychological distress in patients with cancer. Anticipated dropout rates
were 15% in MBCTand TAU, and 30% in eMBCT.19 Given the anticipated
dropout rates, the allocation ratio was 1:1.2:1. Patients randomly assigned
to receive TAU were secondarily randomly assigned to MBCT or eMBCT,
to be given after the TAU period of 3 months. The study was approved by
the ethical review board of the Radboud University Medical Center (CMO
Arnhem-Nijmegen 2013/542). All centers provided local ethics approval.
The study was registered on Clinicaltrials.gov (NCT02138513) shortly after
the start of recruitment and was reported following CONSORT guide-
lines.20 A protocol article was published in advance of trial completion.21
Participants
Inclusion criteria were (1) a cancer diagnosis, any tumor type or
stage, at any time, receiving or not receiving treatment; (2) a score of$ 11
on the Hospital Anxiety and Depression Scale (HADS); (3) computer
literacy and Internet access; (4) ability to participate in both MBCT and
eMBCT; and (5) good command of the Dutch language. Exclusion criteria
were (1) severe psychiatric morbidity, such as suicidal ideation and/or
current psychosis; (2) change in psychotropic medication within a period
of 3 months before baseline; and (3) previous participation in four or more
sessions of an MBI.
Procedure
Patients were recruited from April 2014 to December 2015 via health
care professionals in six centers (n = 64; 26%) via online media (n = 49;
20%), offline media (n = 44; 18%), patient associations (n = 43; 18%), and
peers (n = 27; 11%). Eighteen patients (7%) could not remember how they
heard about the study. Interested patients filled out the HADS on the
research Web site. Patients with HADS $ 11 received a phone call from
one of the researchers, during which the remaining inclusion and ex-
clusion criteria were assessed. Once patients provided oral and written
consent and had completed the baseline assessment, they were randomly
assigned to MBCT, eMBCT, or TAU and informed about their allocation
by E.B.
Intervention
Face-to-face MBCT. The MBCT protocol6 was tailored to patients
with cancer by including cancer-related psychoeducation and adapted
movement exercises. The MBCT consisted of eight weekly 2.5-hour group
sessions, a 6-hour silent day, and daily home practice assignments guided
by audio files. Each participant in both interventions received a folder with
information on each session.
Internet-based mindfulness-based cognitive therapy. The eMBCT was
delivered individually and included weekly asynchronous written in-
teraction with a therapist over e-mail. Patients were granted access to
a secure Web site containing material for 8 weeks plus a silent day and an
inbox. Each session included an introduction and daily meditation ex-
ercises with meditation audio files. Patients were asked to practice and fill
out practice diaries on a daily basis. They were provided with (fictional)
patients’ descriptions to emphasize common experiences and clarify the
use of the diaries. Patients were given written instructions after week 5 to
prepare for their silent day at home. In the week of the silent day, patients
were provided with a program similar to theMBCTsilent day. At the end of
the silent day, eMBCT patients wrote about their experiences in an essay.
The therapist provided written feedback on the completed forms and the
essay via the secured inbox on a prearranged day of the week. Having
completed four or more sessions of MBCT was defined as a minimum
adequate dose in both interventions.22
Treatment as usual. TAU consisted of all health care that patients
usually received. Except for not participating in MBIs during the study
period, there were no restrictions on health care utilization. Data on health
care utilization were gathered using the Trimbos/iMTA questionnaire for
Costs associated with Psychiatric illnesses.23
Therapists
Fourteen therapists participated: seven provided both interventions,
two only provided MBCT, and five only provided eMBCT. All therapists
fulfilled the criteria of the UK Mindfulness-Based Teacher Therapist
Network Good Practice Guidelines for teaching MBIs.24 Three full-day
supervision meetings were held during the intervention phase of the trial.
All face-to-face MBCT sessions were videotaped to evaluate therapist
competency using the Mindfulness-Based Interventions-Teachers As-
sessment Criteria.25 Therapist competency levels were determined by two
independent therapists who evaluated two random sessions from each of
the nine therapists providing face-to-face MBCT (who treated 80.8% of all
patients receiving either intervention). Interrater reliability was .72. Of the
nine therapists rated, four were considered proficient (n = 64 patients),
three were considered competent (n = 64 patients), and two were con-
sidered beginner (n = 7 patients).
Measures
Primary outcome. Psychological distress was measured with the
HADS, a 14-item self-report scale designed to assess anxiety and de-
pression inmedical outpatients.26,27 It has good psychometric properties in
the general medical population, including patients with cancer in palliative
care.28 The internal consistency in this sample was high (a = .87).
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Secondary outcomes. Psychiatric diagnosis was assessed by the
Structured Clinical Interview for DSM-IV-TR Axis I Disorders.29 The
Structured Clinical Interview for DSM-IV-TR Axis I Disorders was ad-
ministered by a trained interviewer who completed a Master in Behavioral
Science degree (F.C.), supervised by either an experienced psychiatrist (E.B.
or A.S.) or psychologist (M.v.d.L.). All interviews were audiotaped. Fear of
cancer recurrence was assessed with the severity subscale of the Fear of
Cancer Recurrence Inventory.30,31 Rumination was measured by the ru-
mination subscale of the Rumination and Reflection Questionnaire;32
health-related quality of life was measured by the mental and physical
scales of the Short-Form 1233 using Dutch norm scores from a clinical
sample;34 mindfulness skills were measured by the Five Facet Mindfulness
Questionnaire-Short Form;35 and positive mental health was measured by
the Mental Health Continuum-Short Form.36 As a potential moderator,
neuroticismwasmeasured by the Neuroticism Extraversion Openness-Five
Factor Inventory.37 Further details of the measures used are included in the
study protocol (Data Supplement).21
Sample Size
The sample size calculation was based on previous postintervention
HADS scores of patients with cancer who received MBCT at the Helen
Dowling Institute (mean, 10.6; standard deviation [SD], 6.4) compared
with those who had not received it (mean, 14.8; SD, 8.1). With 90% power,
65 patients per condition were needed. Because of anticipated differential
dropout rates among treatment arms, the recruitment target was 245
patients: 76 in each of theMBCTand TAU arms, and 93 in the eMBCTarm.
Randomization and Blinding
Once patients provided oral and written consent and completed the
baseline assessment, they were randomly assigned to MBCT, eMBCT, or
TAU by a computer-generated allocation sequence designed by an in-
dependent biostatistician. This custom software was accessed by one of the
researchers (E.B.) via a study-specific Web site. Randomization was carried
out with a fixed block size of 16 stratified for region andminimized for sex,
cancer diagnosis (breast v other), and anticancer treatment intent (curative
v palliative). After randomization, E.B. informed patients of their allo-
cation by e-mail. E.B. planned and invited participants to the follow-up
assessments; the standardized psychiatric interviews were conducted by
F.C. and research assistants who were blinded to treatment allocation. Both
E.B. and F.C. instructed patients not to mention their treatment condition
at the beginning of each psychiatric interview.
Statistical Analysis
Statistical analyses were carried out using Statistical Package for the
Social Sciences (SPSS) version 22 (SPSS, Chicago, IL). Differences among
conditions in demographic and clinical variables were tested by x2 analysis
and t tests. Continuous outcomes were analyzed with linear mixed
modeling in a model with uncorrelated residual errors and random in-
tercepts, including group allocation and its interaction with time and
stratification (region) and minimization (sex, cancer diagnosis, anticancer
treatment intent) variables as fixed factors. Because both MBCT and
eMBCT were compared with TAU, the two-sided type I error rate was
corrected to .025 for the two direct (MBCTand eMBCT) comparisons with
TAU. All reported analyses used the intent-to-treat sample. Missing
continuous outcomes were imputed with automatic multiple imputation
on the basis of linear regression (20 iterations). The multiple imputation
data set was considered the primary data set. Cohen’s d effect sizes were
calculated using postintervention means and baseline pooled SDs. These
statistics are commonly used in psychological contexts to compare effect
sizes across studies,38 and in accordance with Cohen’s guidelines,
Cohens’s d effect sizes were interpreted as small (0.2 to 0.5), medium (0.5
to 0.8), or large (. 0.8).39
In addition, the reliable change index (RCI) was calculated by di-
viding the observed difference score by the SE of measurement. Each
participant was categorized as improved (RCI,21.96), no change (21.96
to 1.96), or deteriorated (RCI . 1.96).40 Improvements in terms of
psychiatric diagnosis and RCI were assessed using x2 analyses.
Exploratory moderation analyses of dropout were performed using
logistic regression, including an interaction term between completer (yes/
no) and possible moderators: sex, age, cancer diagnosis, anticancer
treatment intent, psychiatric diagnosis, neuroticism, and therapist. Ex-
ploratory moderation analyses of the primary outcome were performed by
including a three-way interaction term among condition, time, and
possible moderators: sex, age, cancer diagnosis, anticancer treatment in-
tent, psychiatric diagnosis, neuroticism, and therapist. First, moderators
were assessed in two separate analyses of either intervention compared
with TAU. Second, moderators were assessed in analyses of the two in-
tervention conditions only.
RESULTS
Study Sample
In total, 532 patients were screened with the HADS (Fig 1), of
whom 98 (18.4%) were excluded for scoring, 11. Of 434 patients
who were contacted by telephone, 24 (5.5%) were excluded be-
cause of previous experience with mindfulness, 22 (5.1%) could
not be contacted, and 95 (21.9%) declined participation because of
possible traveling distance (n = 55; 12.7%); strong randomization
preference (n = 12; 2.8%), of whom four had a preference for
eMBCT and eight for in-person group MBCT; and scheduling
difficulties (n = 11; 2.5%). Of the remaining 293 patients, another
10 (3.4%) could not be contacted, and 38 (13.0%) declined
participation after the baseline assessment. There were no significant
differences in mean HADS scores between the 133 decliners (mean,
20.4; SD, 5.6) and those who were randomly assigned (mean, 20.6;
SD, 6.2). In total, 245 patients with cancer were randomly assigned
to MBCT (n = 77), eMBCT (n = 90), or TAU (n = 78). The three
conditions did not differ in terms of baseline demographic or clinical
characteristics (Table 1). The number of months between baseline
and postintervention assessments did not differ between MBCT
(mean, 5.4; SD, 2.3) and eMBCT (mean, 5.9; SD, 1.8; P = .13), but
was higher in both intervention conditions than in TAU (mean, 3.5;
SD, 0.9; P , .001).
Seventy of 77 patients (90.9%) started MBCT, and 71 (92.2%)
completed four or more sessions (mean, 7.9; SD, 1.3; Fig 1). Eighty-
two of 90 patients (91.1%) started eMBCTand 71 completed four or
more sessions (mean, 8.6; SD, 12). The amount of estimated daily
minutes of mindfulness practice did not differ significantly between
MBCT (n = 56; mean, 30.6; SD, 26.0) and eMBCT (n = 70; mean,
28.7; SD, 29.3; P = .69). Dropouts from the interventions were
significantly higher in the eMBCT than in the MBCT group: x2(1, n
= 167) = 3.92 (P = .047). Nonresponse on the post-treatment as-
sessment was substantial (16.9% in MBCT, 16.7% in eMBCT, and
10.3% in TAU) but did not differ significantly among conditions (P
= .41). Nonresponders were more often female (P = .033) and had
less education (P = .037) than responders.
Health Care Utilization
There were no significant differences in health care utilization
between the intervention and TAU groups (Table 2), except for the
proportion of patients receiving outpatient treatment (eg, che-
motherapy), which was higher in the TAU group.
jco.org © 2018 by American Society of Clinical Oncology 2415
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Group-based
MBCT
(n = 77; 31.4%)
Completed T1
assessment
(n = 64; 83.1%)
Completed
group-based
MBCT
(n = 64; 83.1%)
Not started
Scheduling
Group unavailable
Medical reason
Other intervention
Deceased
(n = 7; 9.1%)
(n = 2)
(n = 2)
(n = 1)
(n = 1)
(n = 1)
Discontinued
(< 4 sessions)
No motivation
Medical reason
Too burdensome
MBCT experience
(n = 6; 7.8%)
(n = 2)
(n = 2)
(n = 1)
(n = 1)
Lost to follow-up
No reason provided
Withdrawal
Medical reason
Authors’ mistake
Deceased
(n = 13; 16.9%)
(n = 5)
(n = 4)
(n = 2)
(n = 1)
(n = 1)
Internet-based
MBCT
(n = 90; 36.7%)
Completed T1
assessment
(n = 75; 83.3%)
Completed
Internet-based
MBCT
(n = 63; 70.0%)
Not started
Other intervention
No reason provided
Medical reason
Computer difficulties
(n = 8; 8.9%)
(n = 4)
(n = 2)
(n = 1)
(n = 1)
Discontinued
(< 4 sessions)
No motivation
No reason provided
Medical reason
Too burdensome
Computer difficulties
(n = 19; 21.1%)
(n = 6)
(n = 2)
(n = 2)
(n = 3)
Scheduling (n = 3)
(n = 3)
Lost to follow-up
No reason provided
Withdrawal
Medical reason
(n = 15; 16.7%)
(n = 8)
(n = 6)
(n = 1)
Treatment as
usual
(n = 78; 31.8%)
Completed T1
assessment
(n = 70; 89.7%)
Completed
TAU
(n = 77; 98.7%)
Not started (n = 0)
Discontinued
MBCT during TAU
(n = 1; 1.3%)
(n = 1)
Lost to follow-up
No reason provided
Medical reason
Withdrawal
(n = 8; 10.3%)
(n = 4)
(n = 3)
(n = 1)
Randomly assigned
(n = 245)
Unreachable (n = 10)
Declined after baseline
Strong randomization preference
Scheduling difficulties
Not interested after baseline
(n = 38)
(n = 12)
(n = 11)
(n = 15)
Screened
(N = 532)
Eligible
(n = 434)
Baseline assessment
(n = 293)
Ineligible
HADS too low
(n = 98)
(n = 98)
Unreachable (n = 22)
Declined after screening
Travel distance
Unknown/no reason provided
Other services needed
Physical limitations
(n = 95)
(n = 55)
(n = 18)
(n = 12)
(n = 10)
Excluded
Experience with mindfulness
Severe psychiatric morbidity
(n = 24)
(n = 21)
(n = 3)
Fig 1. CONSORT diagram (n = 245). HADS, Hospital Anxiety and Depression Scale; MBCT, mindfulness-based cognitive therapy; TAU, treatment as usual.
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Safety
A total of 21 severe adverse events unrelated to the in-
tervention were reported in the MBCT (n = 6), eMBCT (n = 9),
and TAU (n = 6) groups (Appendix Table A1, online only). One
severe adverse event occurred during the study period: a patient
died after being randomly assigned as a result of illness.
Intervention Outcomes
In between-group comparisons of both interventions com-
pared with TAU, patients in the MBCT and eMBCT conditions
reported significantly less psychological distress postintervention
than did those receiving TAU, with small to medium effect sizes
(Cohen’s d, .45 and .71, respectively; Table 3; Fig 2). The pro-
portion of patients demonstrating reliable improvement was sig-
nificantly greater inMBCT than TAU (36% v 14%; x2[1, n = 134] =
8.44; P = .004) and in eMBCT than TAU (37% v 14%; x2[1, n =
145] = 9.95; P = .002). Improvement in rates of psychiatric di-
agnosis favored both interventions comparedwith TAU but were not
statistically significant (MBCT: 32% v 16%; x2[1, n = 126] = 4.73;
P = .030; and eMBCT: 29% v 16%; x2[1, n = 138] = 3.15; P = .076).
Compared with TAU, both MBCT and eMBCT significantly
reduced fear of cancer recurrence (Cohen’s d, .27 and .53, re-
spectively), rumination (Cohen’s d, .42 and .51, respectively), and
improved mental health–related quality of life (Cohen’s d, .59 and
.67, respectively), but not physical health–related quality of life
(Cohen’s d, .35 and .24, respectively). They also resulted in better
mindfulness skills (Cohen’s d, .47 and .82, respectively) and in-
creased positive mental health compared with TAU (Cohen’s d, .12
and .44, respectively).
Moderation
Exploratory analyses yielded no significant moderation of
intervention dropout or primary outcome in the analyses com-
paring both interventions with TAU separately (all Ps . .05),
except for neuroticism. In the analyses comparing either MBCT
interventions with TAU, there was a significant interaction between
neuroticism and intervention condition (MBCT v TAU P = .014;
eMBCT v TAU P = .004). Patients scoring higher on neuroticism
on baseline improved more on psychological distress in both
intervention conditions than in TAU.
DISCUSSION
To our knowledge, this is the first study to simultaneously compare
MBCT and eMBCT with TAU in a large sample of distressed
heterogeneous patients with cancer. Both MBCT and eMBCT
resulted in a statistically significant and clinically reliable reduction
of psychological distress compared with TAU (Table 4). Both
interventions demonstrated similar reductions of fear of cancer
recurrence, rumination, and improvements in mental (but not
physical) health–related quality of life, mindfulness skills, and
positive mental health compared with TAU.
Our study confirms previous findings regarding the effec-
tiveness of eMBIs for patients with cancer.14,19 Although the
group-based setting is considered important for MBIs,41 this study
suggests that individual guided eMBCT with limited teacher
feedback is also effective, thus improving the accessibility of this
intervention for patients with cancer. However, eMBCT did result
in higher dropout rates than MBCT. Exploratory analyses did not
yield any moderators of intervention dropout. Furthermore,
qualitative research examining the reasons for dropout is critical to
improve the efficacy of Web-based interventions.42
A strength of this study is the patient-centered nature of the
recruitment across multiple regions because in previous research,
we encountered difficulties with consecutive sampling of patients
in hospital outpatient settings.43 Other strengths are that the in-
terventions followed strict protocols, they were delivered by
qualified therapists, and therapist competency was rated by two
Table 1. Baseline Sociodemographic and Clinical Characteristics (n = 245)
Characteristic
All
(n = 245)
MBCT
(n = 77)
eMBCT
(n = 90)
TAU
(n = 78) P
Sex .912
Female 210 (85.7) 67 (87.0) 77 (85.6) 66 (84.6)
Male 35 (14.3) 10 (13.0) 13 (14.4) 12 (15.4)
Age (years) .464
Mean 51.7 52.1 52.4 50.4
SD 10.7 11.4 10.7 9.9
Married/in a
relationship
.491
Yes 202 (82.4) 65 (84.4) 76 (84.4) 61 (78.2)
No 43 (17.6) 12 (15.6) 14 (15.6) 17 (21.8)
Children .314
Yes 169 (69.0) 48 (62.3) 65 (72.2) 56 (71.8)
No 76 (31.0) 29 (37.7) 25 (27.8) 22 (28.2)
Education .451
High 166 (67.8) 54 (70.1) 56 (62.2) 56 (71.8)
Middle 77 (31.4) 22 (28.6) 34 (37.8) 21(26.9)
Low 2 (0.8) 1 (1.3) 0 1(1.3)
Diagnosis .724
Breast cancer 151 (61.6) 53 (68.8) 53 (58.9) 45 (57.7)
Gynecologic cancer 18 (7.3) 2 (2.6) 9 (10.0) 7 (9.0)
Prostate cancer 16 (6.5) 6 (7.8) 7 (7.8) 3 (3.8)
Colon cancer 12 (4.9) 4 (5.2) 4 (4.4) 4 (5.1)
Non-Hodgkin’s
lymphoma
11 (4.5) 1 (1.3) 3 (3.3) 7 (9.0)
Skin cancer 5 (2.0) 1 (1.3) 3 (3.3) 1 (1.3)
Thyroid cancer 4 (1.6) 1 (1.3) 1 (1.1) 2 (2.6)
Bladder cancer 4 (1.6) 1 (1.3) 2 (2.2) 1 (1.3)
Neuroendocrine
tumor
4 (1.6) 1 (1.3) 2 (2.2) 1 (1.3)
Other 20 (8.2) 7 (9.1) 6 (6.7) 7 (9.0)
Years since
diagnosis
.616
Mean 3.5 3.9 3.3 3.2
SD 4.7 5.7 4.0 4.3
Anticancer
treatment
intent
.472
Curative 206 (84.1) 68 (88.3) 74 (82.2) 64 (82.1)
Palliative 39 (15.9) 9 (11.7) 16 (17.8) 14 (17.9)
Current treatment .694
None 133 (53.1) 43 (55.8) 49 (54.4) 41 (52.6)
Hormone therapy 79 (32.2) 22 (28.6) 28 (31.1) 29 (37.2)
Combination of
treatments
12 (4.9) 4 (5.2) 4 (4.4) 4 (5.1)
Immunotherapy 9 (3.7) 1 (1.3) 5 (5.6) 3 (3.8)
Radiotherapy 8 (3.3) 5 (6.5) 3 (3.3) 0
Chemotherapy 4 (1.6) 2 (2.6) 1 (1.1) 1 (1.3)
NOTE. Data presented as No. (%).
Abbreviation: eMBCT, Internet-based mindful-based cognitive therapy; MBCT,
mindfulness-basedcognitive therapy; SD, standarddeviation; TAU, treatment asusual.
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independent, experienced therapists. We systematically collected
data on health care utilization during the study. The study used
a broad array of outcome measures, including both observer-rated
interviews and self-report questionnaires.
In addition to these strengths, the study has some limi-
tations. The study was not powered to directly compare the two
interventions or determine noninferiority of eMBCT to MBCT,
because this would have required a larger sample size. As with other
psycho-oncology research, the majority of the participants were
middle-aged patients with breast cancer. Although this is in line with
the characteristics of patients with cancer seeking psychosocial
support,44 this might limit generalizability to patients with other
Table 3. Mean Scores at Baseline and Postintervention (both listwise deletion and pooledmultiple imputation scores are depicted) and Between-Group Differences for
Primary and Secondary Outcome Measures
Outcome Measure
Groups Linear Mixed Modeling: Between-Group Differences
MBCT eMBCT TAU P* TAU-MBCT TAU-eMBCT
No. M SD† No. Mean SD† No. Mean SD† Overall Est. SE P ES Est. SE P ES
Primary
HADS
T0 77 18.81 6.70 90 17.24 7.07 78 17.04 5.79
T1 original 64 13.25 6.33 75 11.87 6.16 70 16.37 6.50 , .001 4.65 1.00 , .001 0.50 4.63 .96 , .001 0.70
T1 imputed 77 13.69 0.78 90 11.88 0.69 78 16.48 0.78 , .001 4.56 1.02 , .001 0.45 4.81 .95 , .001 0.71
Secondary
FCRI severity
T0 77 21.49 6.55 90 21.20 5.80 77 21.13 7.28
T1 original 64 18.05 6.49 75 17.28 7.33 68 20.66 7.10 , .001 2.27 0.86 .009 0.38 3.34 .82 , .001 0.51
T1 imputed 77 18.65 0.79 90 17.06 0.81 78 20.53 0.84 , .001 2.23 0.89 .013 0.27 3.52 .84 , .001 0.53
RRQ rumination
T0 77 44.04 7.96 90 43.09 8.17 77 42.69 8.56
T1 original 64 37.61 8.16 75 36.81 8.90 68 41.65 8.85 , .001 4.87 1.14 , .001 0.49 4.85 1.10 , .001 0.58
T1 imputed 77 38.12 1.04 90 37.26 0.97 78 41.56 1.05 , .001 4.77 1.20 , .001 0.42 4.68 1.14 , .001 0.51
SF-12 Mental
T0 77 32.48 10.19 90 34.50 12.15 78 34.74 11.10
T1 original 64 43.41 9.67 72 44.17 9.95 63 36.78 11.31 , .001 28.89 2.01 , .001 0.62 27.88 1.95 , .001 0.64
T1 imputed 77 42.71 1.23 90 44.25 1.21 78 36.42 0.95 , .001 28.55 1.98 , .001 0.59 28.07 1.92 , .001 0.67
SF-12 Physical
T0 77 46.06 8.88 90 45.62 10.25 78 45.40 8.24
T1 original 64 48.24 8.45 72 48.19 10.51 63 45.24 9.77 .343 22.14 1.61 .19 0.35 21.91 1.57 .22 0.32
T1 imputed 77 48.43 1.11 90 47.60 1.20 78 45.40 1.21 ..05 22.38 1.61 .14 0.35 21.99 1.57 .21 0.24
FFMQ-SF total
T0 77 72.43 9.69 90 76.39 10.87 77 75.75 11.18
T1 original 64 82.02 10.42 75 85.52 11.94 70 77.26 11.80 , .001 28.03 1.76 , .001 0.45 28.06 1.69 , .001 0.75
T1 imputed 77 81.61 1.29 90 85.75 1.33 78 76.73 1.41 , .001 28.17 1.82 , .001 0.47 28.35 1.70 , .001 0.82
MHC-SF total
T0 77 34.05 12.39 90 37.16 13.77 77 37.56 12.46
T1 original 64 40.02 12.39 75 43.53 13.14 70 37.86 13.34 .001 25.19 1.71 .003 0.17 26.10 1.64 , .001 0.43
T1 imputed 77 38.85 1.51 90 43.13 1.46 78 37.36 1.59 , .005 24.97 1.71 .004 0.12 26.15 1.66 , .001 0.44
Abbreviations: ES, effect size; Est., estimate; FCRI, Fear of Cancer Recurrence Inventory; FFMQ, Five Facet Mindfulness Questionnaire-Short Form; HADS, Hospital
Anxiety and Depression Scale; eMBCT, Internet-based mindful-based cognitive therapy; MBCT, mindfulness-based cognitive therapy; MHC-SF, Mental Health
Continuum-Short Form; RRQ, Rumination and Reflection Questionnaire; SD, standard deviation; SF-12, Short Form-12; TAU, treatment as usual.
*Because both MBCT and eMBCT were compared with TAU, the two-sided type I error rate was corrected to .025.
†SE for imputed means.
Table 2. Health Care Utilization During the Intervention Period for MBCT, eMBCT and TAU Groups
Utilization
All (n = 198) MBCT (n = 63) eMBCT (n = 72) TAU (n = 63)
P*No. % No. % No. % No. %
Hospital outpatient consultation 153 77 45 71 61 85 47 75 .153
Hospital overnight 13 7 4 9 4 6 5 8 .853
Hospital outpatient treatment 36 18 6 10 12 17 18 29 .020
Hospital emergency department 7 4 1 1 3 3 3 4 .588
Mental health care† 62 31 18 29 24 33 20 32 .834
General practitioner 116 59 35 56 39 54 42 67 .285
Physical therapist 92 47 29 46 40 56 23 37 .086
Complementary care 56 28 21 33 20 28 15 34 .491
Abbreviations: eMBCT, Internet-based MBCT; MBCT, mindfulness-based cognitive therapy; TAU, treatment as usual.
*Pearson x2 test.
†Social worker, psychologist.
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types of cancer. Because one inclusion criterion was the ability and
willingness to attend both MBCT and eMBCT, the sampling frame
for the current study was probably not representative of patients who
would prefer eMBCT in clinical practice. Because treatment pref-
erence is often positively correlated with treatment outcome,45 we
would expect that this RCT underestimated rather than over-
estimated the effects of eMBCT.
In terms of research implications, long-term results should be
gathered to examine the stability of effects. In addition, data on
cost-utility of MBIs in patients with cancer should be collected.46
Internet interventions do not involve the costs of transportation,
traveling time, space, equipment, cleaning, and other overhead
expenses and thus could be more cost effective. Possible mediators of
the effect, such as mindfulness skills or rumination, should be further
investigated.47,48 Moreover, mediation analyses could also examine
possible differences in adherence in both MBCT and eMBCT.
In terms of clinical implications, implementation of eMBCT
could make MBIs more accessible for patients with cancer without
having to compromise intervention efficacy. However, intervention
dropout could possibly be improved by the delivery mode of
eMBIs.49 Qualitative work demonstrates that aspects such as the
individual nature and the asynchronous interaction of the eMBCT
used in this study are helpful for some patients.50 Future studies
should assess how different eMBCT designs (eg, blended designs
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Fig 2. Change in Hospital Anxiety and
Depression Scale (HADS) scores be-
tween baseline and postintervention for
(A) mindfulness-based cognitive therapy
(MBCT), (B) Internet-based mindful-based
cognitive therapy (eMBCT), and (C) treat-
ment as usual (TAU) groups. The blue di-
agonal line represents no change in HADS
between baseline and postintervention,
and the gray upper and lower lines repre-
sent the upper (above indicates de-
teriorated) and lower (below indicates
improved) bounds of the 95% CI of the
Jacobson-Truax reliable change index (RCI).
Table 4. Clinically Significant Improvement Measured by Jacobson-Truax Reliable Change Index on HADS and Psychiatric Diagnosis Between Baseline and Post-
intervention for MBCT, eMBCT, and TAU Groups
Improvement
Reliable Change Index (n = 209) Psychiatric Diagnosis (n = 202)
MBCT
(n = 64)
P*
eMBCT
(n = 75)
P*
TAU
(n = 70)
MBCT
(n = 64)
P*
eMBCT
(n = 76)
P*
TAU
(n = 62)
No. % No. % No. % No. % No. % No. %
Improved 23 36 .004 28 37 .002 10 14 21 33 .030 22 29 .076 10 16
No change 39 61 47 63 54 77 34 67 50 66 49 79
Deteriorated 2 3 .184 0 0 .010 6 9 0 0 .075 4 5 .910 3 5
Abbreviations: eMBCT, Internet-based MBCT; HADS, Hospital Anxiety and Depression Scale; MBCT, mindfulness-based cognitive therapy; TAU, treatment as usual.
*Between group x2 tests for the respective condition compared with TAU.
jco.org © 2018 by American Society of Clinical Oncology 2419
MBCT and Internet-Based MBCT for Patients With Cancer
Downloaded from ascopubs.org by Radboud University Nijmegen on January 21, 2020 from 131.174.248.154
Copyright © 2020 American Society of Clinical Oncology. All rights reserved.
combining the advantages of face-to-face and Internet-based el-
ements)51 could further improve intervention accessibility, ad-
herence, and effectiveness.50
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Appendix
Table A1. Adverse Events Reported per Condition
Participant MBCT (n = 9) eMBCT (n = 6) TAU (n = 9)
Intervention completer Pneumonia (n = 1) Questionnaires too burdensome (n = 2) Illness progression (n = 3)
Cancer recurrence (n = 1) Needed additional psychological help (n = 1) Questionnaires too burdensome (n = 3)
Questionnaires too burdensome (n = 4) Needed additional psychological help (n = 2)
Reported high distress (n = 1)
Intervention dropout Surgery (n = 1) Illness progression (n = 1)
Deceased (n = 1) Unspecified medical reason (n = 2)
Unspecified medical reason (n = 1)
Abbreviations: eMBCT, Internet-based MBCT; MBCT, mindfulness-based cognitive therapy; TAU, treatment as usual.
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